伊立替康联合卡培他滨二线治疗晚期胃癌

目的探讨伊立替康（CPT-11）联合卡培他滨二线治疗晚期胃癌的近期疗效及不良反应。方法对30例晚期胃癌患者给予CPT-11 180mg·m^-2于化疗第1天静脉滴注90min；卡培他滨1250mg·m^-2，分早晚2次口服，连服14d，21d为1个周期。每2个周期后进行评价疗效。治疗期间进行不良反应评估。结果30例患者中25例可评价疗效，其中完全缓解1例，部分缓解9例，稳定10例，进展5例，总有效率为40．0％，临床反应率为80．0％。常见不良反应为中性粒细胞减少、迟发性腹泻、恶心、呕吐和手足综合征等，多为Ⅰ～Ⅱ度。结论CPT-11联合卡培他滨二线治疗进展期胃癌，疗效较好，不良反应可耐受，且用药方便，值得临床广泛推广应用。

Irinotecan combined with capecitabine in line-2 treatment of locally advanced or metastatic gastric cancer

Aim To observe the short- term efficacy and safety of irinotecan （CPT-11 ） combined with capeeitabine in line-2 treatment of patients with locally advanced or metastatic gastric cancer. Methods 30 evaluable patients with locally advanced or metastatic gastric cancer received CPT-11 （ 180 mg· m^-2 iv gtt） on day 1 and capecitabine （ 1 250 mg · m ^-2 ,po bid） on days 1 to 14. One cycle was 21 days. After every two cycles, therapeutic efficacy was evaluated. Adverse reactions were assessed during treatment. Results In 25 evaluable cases among the 30 patients, 1 case had complete remission,9 cases partial response, 10 cases stable disease and 5 cases with progressive disease. The total efficiency rate was 40.0% , and the clinical response rate was 80.0%. The main adverse reactions were neutropenia,delayed diarrhea,nausea,vomiting and hand -foot syndrome,most of which were at Ⅰ - Ⅱ degree. Conclusions CPT-11 combined with capecitabine in line-2 treatment of patients with locally advanced or metastatic gastric cancer can get better efficacy with tolerated adverse reactions and convenient medication. It is worthy of wider application.